Jiangsu Hengrui Pharmaceuticals Co Ltd, a prominent player in the healthcare sector, is headquartered in Lianyungang, China. The company is renowned for its specialization in the development, manufacturing, and marketing of a diverse array of pharmaceutical products and medicine packaging materials. Its product portfolio encompasses anti-tumor medicines, pain-killers, anti-infection medicines, and aluminum foil, among other related products. For further details on their offerings, interested parties can visit their official website at www.hrs.com.cn .
As of April 23, 2026, Jiangsu Hengrui Pharmaceuticals Co Ltd’s close price on the Hong Kong Stock Exchange was recorded at 68.85 HKD. The company’s stock has experienced significant fluctuations over the past year, with a 52-week high of 95.2 HKD on October 1, 2025, and a 52-week low of 50.2 HKD on May 11, 2025. The market capitalization of the company stands at a substantial 456,971,190,272 HKD, reflecting its significant presence in the pharmaceutical industry.
Jiangsu Hengrui Pharmaceuticals Co Ltd is listed on the Shanghai Stock Exchange, with its initial public offering (IPO) taking place on September 7, 2000. Despite its notable market presence, the company has not been featured in any recent market coverage or analyst reports within the provided materials. The focus of these reports has been on other Hong Kong-listed companies, highlighting their ratings, earnings outlooks, and strategic developments, without any mention of Jiangsu Hengrui Pharmaceuticals.
In summary, Jiangsu Hengrui Pharmaceuticals Co Ltd remains a key entity in the pharmaceutical sector, with a broad range of products and a significant market capitalization. However, the absence of recent financial updates or analyst coverage in the provided materials suggests a need for stakeholders to seek additional sources for the latest insights into the company’s performance and strategic direction.
